GHRP-2
MetabolicMetabolic-medicine specialists evaluate GHRP-2 against glycemic control, insulin sensitivity, visceral adiposity, and the broader cardiometabolic risk profile. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin.. Baseline labs (HbA1c, fasting glucose, fasting insulin, HOMA-IR, lipid panel, ALT/AST, hsCRP) with 6-8 week follow-up on the 100-300 mcg 2-3x daily subq protocol provide the clinical evaluation framework.
Key Takeaways
Metabolic lens: GHRP-2 is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 100-300 mcg 2-3x daily subq via subq. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. The metabolic medicine framework evaluates GHRP-2 against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.
Insulin signalling and glycemic effect
GHRP-2's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
Weight management and the appetite circuit
Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.
Visceral fat and the cardiometabolic axis
GHRP-2's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
In the metabolic syndrome population, GHRP-2 for insulin sensitivity produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
GHRP-2 for type 2 diabetes research is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
Where GHRP-2 is used for glp-1 synergy, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
In the metabolic syndrome population, GHRP-2 for metabolic syndrome produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-300 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-300 mcg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 100-300 mcg | 2-3x daily SubQ |
| Maintenance phase | SubQ | 70-300 mcg | Ongoing with periodic pauses |
Dose timing for GHRP-2 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
GHRP-2 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- GHRP-2 + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with GHRP-2's mechanism in metabolic / endocrine protocols.
- GHRP-2 + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with GHRP-2's mechanism in metabolic / endocrine protocols.
- GHRP-2 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with GHRP-2's mechanism in metabolic / endocrine protocols.
- GHRP-2 + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with GHRP-2's mechanism in metabolic / endocrine protocols.
More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy.
Lens-specific safety considerations for metabolic / endocrine use of GHRP-2: More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| GHRP-2 | Growth hormone releasing peptide | ~15-60 min | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Is GHRP-2 appropriate alongside metformin or other diabetes medications?
How does GHRP-2 affect glycemic control?
What metabolic labs should I track?
Pancreatitis or thyroid risk?
What is the mechanism of action of GHRP-2?
What class of compound is GHRP-2?
Start a GHRP-2 Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified GHRP-2 and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 817 Da
- Sequence length
- 6 aa
- Half-life
- ~15-60 min
- WADA
- Banned (S2)
- FDA
- Approved in Japan for GH stimulation testing only
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-2 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for GHRP-2
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised